Published Special Issue
Expired Date:
Apr. 30, 2016
Order the Hard Copy
Special Issues
Expand the Popularity of Your Conference
Publish conference papers as a Special Issue
Send your Special Issue proposal to:
Submit Hot Topics
If you wish to order hard copies, please click here to know more information.
Home / Journals / American Journal of Health Research / Mycobacterial Drug Resistance
Mycobacterial Drug Resistance
Lead Guest Editor:
Anand Kumar Maurya
Department of Microbiology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
Guest Editors
Vijaya Lakshmi Nag
Department of Microbiology, All India Institute of Medical Sciences
Jodhpur, Rajasthan, India
Surya Kant
Department of Pulmonary Medicine, King George’s Medical University
Lucknow, Uttar Pradesh, India
Ram Awadh Singh Kushwaha
Department of Pulmonary Medicine, King George’s Medical University
Lucknow, Uttar Pradesh, India
Amresh Kumar Singh
Department of Microbiology, BRD Medical College
Gorakhpur, Uttar Pradesh, India
S.M. Wasiur Rahman
Qatif Central Hospital, Ministory of Health
Dammam, Saudi Arabia
Santosh Kumar
Department of Biosciences, University of Texas
Texas, USA
Vikram Saini
Department of Microbiology, University of Alabama at Birmingham
Birmingham, USA
Mikiyas Amare Getu
Department of Nursing, Woldia University
Woldia, Ethiopia
Kranthi Kunkalla
Department of Hematopathology, University of Miami
Miami, FL - Florida, USA
Ameer Khusro
Department of Plant Biology and Biotechnology, Loyola College, University of Madras
Chennai, Tamil Nadu, India
Fahriye Keskin
Department of Microbiology, Dentistry Faculty, Istanbul University
İstanbul, Turkey
Tuberculosis (TB) remains one of the leading causes of morbidity and mortality worldwide, and resistance to commonly used antituberculous drugs is increasing. DR-TB is a major threat to global public health as it is difficult to treat and often results in relapse or treatment failure. It is also a risk factor for the emergence of Multidrug-resistant tuberculosis (MDR-TB) that does not respond to at least isoniazid and rifampicin and Extensively drug-resistant TB (XDR-TB) defined as infection with MDR-TB strains additionally resistant either to a new-generation fluoroquinolone and an injectable agent or to three of the six main classes of second-line drugs.

The diagnosis of MDR and XDR TB is based on mycobacterial culture and drug susceptibility testing on liquid or solid media, with results available in weeks to months. To address such delay in TB diagnosis as well as to discretely improve the diagnosis accuracy, early detection of DR-TB allows starting of a proper treatment, which has an impact in the better control of the disease. Rapid molecular methods are available for detecting drug-resistant TB, shorter turnaround time, no need for growth of the organism, possibility for direct application in clinical samples, less biohazard risks, and feasibility for automation.

The aim of special issue is to collect excellence of latest research contributions in the field of Mycobacterial Drug Resistance. We are interested in Original research, Review, Short communications, Short reports, Technical notes, case reports and others are solicited in the following areas:

1. Epidemiology of DR-TB
2. Biologic and Molecular mechanism of DR-TB
3. Diagnosis of DR-TB: Conventional and Genotypic Methods
4. Potential Causes and Predictors for The Development of DR-TB
5. Newer Diagnostics for Technologies and Tools for DR-TB
6. Treatment and management of DR-TB
7. Prevention of nosocomial transmission of DR-TB
8. Newer anti-TB drugs for DR-TB
9. TB and HIV Co-Infection
10. Tuberculosis Infection and Reinfection
11. Immunology in Tuberculosis
12. Advances in Tuberculosis Research
13. Molecular epidemiology
14. Vaccine development
15. Antimicrobial Susceptibility Testing and Therapy of Infections with Nontuberculous Mycobacteria
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186